Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group.
Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group.
复制标题
Deprenyl 对减缓帕金森病残疾进展的作用：DATATOP 研究。
DOI：
10.1111/j.1600-0404.1991.tb05025.x
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
LeWitt,PA
中科院分区：
文献类型：
--
作者：
LeWitt,PA
北美DATATOP* 项目研究了800名轻度帕金森病患者的队列，得出结论认为，使用10 mg/天的丙炔苯丙胺可以减缓残疾进展。这项对照临床试验的中期结果是在参与者接受平均12个月的治疗后报告的。该研究发现，Deprenyl治疗几乎将达到帕金森症阶段的风险减半，在该阶段开始左旋多巴治疗对于减轻残疾至关重要。除本研究终点外，其他评级支持慢性丙炔苯丙胺（DP）方案的临床结局改善。34名研究者在受试者接受药物治疗时和4周洗脱期后进行了临床评价。尽管一些受试者从DP中出现了帕金森综合征的轻度症状改善，但这些效应不足以解释DP治疗组延迟达到研究终点的原因。除DP外，这项安慰剂对照双盲研究还评估了另一种抗氧化策略（2，000 I）的保护作用的可能性。U./每天服用α-生育酚多巴胺的单胺氧化酶B型（MAO B）代谢产生过氧化氢，从而对黑质纹状体多巴胺能神经元产生氧化应激。DP对MAO B的抑制可能是减缓帕金森病进展的手段，尽管其他机制也是成立的。DATATOP指出了阻止帕金森病进展的潜力，并提供了一个无与伦比的机会来研究未经治疗的帕金森病的临床过程和神经化学指标。DP的作用是否完全通过抑制MAO B发挥，这是一项与DATATOP相似的试验的主题，该试验计划对另一种选择性MAO B抑制剂进行比较分析。* DATATOP：“Deprenyl和生育酚抗氧化治疗帕金森病”。
Studying a cohort of 800 mildly‐affected parkinsonians, the North American DATATOP* project has concluded that progression in disability can be attenuated by the use of deprenyl, 10 mg/day. Interim results of this controlled clinical trial were reported after participants received treatment for an average of 12 months. The study found that deprenyl treatment almost halved the risk of reaching a stage of Parkinsonism at which the start of levodopa treatment becomes imperative for lessening disability. In addition to this study end‐point, other ratings supported an improved clinical outcome from the chronic deprenyl (DP) regimen. The 34 investigators conducted clinical evaluations both while subjects received medication and after a 4‐week wash‐out. Though some subjects experienced mild symptomatic improvements of Parkinsonism from DP, these effects were insufficient to account for the DP‐treated group's delay at reaching the study end‐point. In addition to DP, this placebo‐controlled double‐blind study also assessed the possibility of protective effects from another antioxidative strategy, a 2,000 I. U./day regimen of alpha‐tocopherol. To date, results of the latter trial have not been reported.Monoamine oxidase type‐B (MAO‐B) metabolism of dopamine generates hydrogen peroxide and, thereby, an oxidative stress on the nigrostriatal dopaminergic neuron. The inhibition of MAO‐B by DP may have been the means by which progression of Parkinsonism was attenuated, although other mechanisms are also tenable. DATATOP has pointed to the potential for arresting the progression of Parkinson's disease, and has provided an unparalleled opportunity to study the clinical course and neurochemical indices of untreated Parkinsonism. Whether DP's effects are enacted entirely through inhibition of MAO‐B is the theme of a trial similar to DATATOP planned for comparative analysis of another selective MAO‐B inhibitor.*DATATOP: “Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism”.